CATALENT INC (CTLT)
US1488061029 - Common Stock
We assign a fundamental rating of 3 out of 10 to CTLT. CTLT was compared to 194 industry peers in the Pharmaceuticals industry. CTLT may be in some trouble as it scores bad on both profitability and health. CTLT has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year CTLT was profitable.
In the past year CTLT had a positive cash flow from operations.
In multiple years CTLT reported negative net income over the last 5 years.
Each year in the past 5 years CTLT had a positive operating cash flow.
1.2 Ratios
CTLT has a better Return On Assets (-4.25%) than 78.65% of its industry peers.
The Return On Equity of CTLT (-11.66%) is better than 75.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.25% | ||
| ROE | -11.66% | ||
| ROIC | N/A |
ROA(3y)-2.82%
ROA(5y)-0.09%
ROE(3y)-8.14%
ROE(5y)-1.42%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CTLT has a Gross Margin (21.82%) which is in line with its industry peers.
CTLT's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for CTLT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 21.82% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.68%
GM growth 5Y-7.41%
2. Health
2.1 Basic Checks
CTLT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CTLT has been increased compared to 1 year ago.
Compared to 5 years ago, CTLT has more shares outstanding
The debt/assets ratio for CTLT is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.55, we must say that CTLT is in the distress zone and has some risk of bankruptcy.
CTLT has a better Altman-Z score (1.55) than 64.06% of its industry peers.
CTLT has a debt to FCF ratio of 49.84. This is a negative value and a sign of low solvency as CTLT would need 49.84 years to pay back of all of its debts.
The Debt to FCF ratio of CTLT (49.84) is better than 78.65% of its industry peers.
A Debt/Equity ratio of 1.38 is on the high side and indicates that CTLT has dependencies on debt financing.
CTLT's Debt to Equity ratio of 1.38 is on the low side compared to the rest of the industry. CTLT is outperformed by 76.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.38 | ||
| Debt/FCF | 49.84 | ||
| Altman-Z | 1.55 |
ROIC/WACCN/A
WACC8.26%
2.3 Liquidity
CTLT has a Current Ratio of 2.51. This indicates that CTLT is financially healthy and has no problem in meeting its short term obligations.
CTLT has a Current ratio of 2.51. This is comparable to the rest of the industry: CTLT outperforms 44.27% of its industry peers.
CTLT has a Quick Ratio of 1.93. This is a normal value and indicates that CTLT is financially healthy and should not expect problems in meeting its short term obligations.
CTLT has a Quick ratio (1.93) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.51 | ||
| Quick Ratio | 1.93 |
3. Growth
3.1 Past
The earnings per share for CTLT have decreased strongly by -61.40% in the last year.
The earnings per share for CTLT have been decreasing by -33.48% on average. This is quite bad
The Revenue has been growing slightly by 4.71% in the past year.
CTLT shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.71% yearly.
EPS 1Y (TTM)-61.4%
EPS 3Y-56.51%
EPS 5Y-33.48%
EPS Q2Q%-30%
Revenue 1Y (TTM)4.71%
Revenue growth 3Y3.1%
Revenue growth 5Y11.71%
Sales Q2Q%4.18%
3.2 Future
Based on estimates for the next years, CTLT will show a very strong growth in Earnings Per Share. The EPS will grow by 73.38% on average per year.
The Revenue is expected to grow by 8.14% on average over the next years. This is quite good.
EPS Next Y346.35%
EPS Next 2Y167.78%
EPS Next 3Y113.72%
EPS Next 5Y73.38%
Revenue Next Year8.24%
Revenue Next 2Y8.09%
Revenue Next 3Y8.48%
Revenue Next 5Y8.14%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 277.18, CTLT can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Earnings ratio of CTLT indicates a somewhat cheap valuation: CTLT is cheaper than 77.60% of the companies listed in the same industry.
CTLT's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 29.20.
Based on the Price/Forward Earnings ratio of 34.02, the valuation of CTLT can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CTLT indicates a somewhat cheap valuation: CTLT is cheaper than 74.48% of the companies listed in the same industry.
CTLT's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 24.00.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 277.18 | ||
| Fwd PE | 34.02 |
4.2 Price Multiples
78.13% of the companies in the same industry are more expensive than CTLT, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, CTLT is valued a bit cheaper than 78.65% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 111.8 | ||
| EV/EBITDA | 34.9 |
4.3 Compensation for Growth
CTLT's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CTLT's earnings are expected to grow with 113.72% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.8
PEG (5Y)N/A
EPS Next 2Y167.78%
EPS Next 3Y113.72%
5. Dividend
5.1 Amount
No dividends for CTLT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CATALENT INC
NYSE:CTLT (11/22/2024, 8:04:01 PM)
After market: 60.98 0 (0%)60.98
+1.32 (+2.21%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap11.07B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 277.18 | ||
| Fwd PE | 34.02 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.8
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.25% | ||
| ROE | -11.66% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 21.82% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.46
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.38 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.51 | ||
| Quick Ratio | 1.93 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-61.4%
EPS 3Y-56.51%
EPS 5Y
EPS Q2Q%
EPS Next Y346.35%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)4.71%
Revenue growth 3Y3.1%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y